- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05235672
Detection of LADA in a Hospital in the Mexican Southeast (LADA patients)
Detection of Latent Autoimmune Diabetes in Adults, Clinical and Metabolic Profile in Patients Treated at the Diabetes Clinic in a Hospital in the Mexican Southeast.
Patients with Latent Autoimmune Diabetes in Adults (LADA) show autoantibodies that indicate an autoimmune pathogenesis. Glutamic acid decarboxylase autoantibodies (GADA) are most prevalent islet autoantibodies in European patients with LADA. In this sense, it is considered that it is sufficient to determine GADA to identify subjects with LADA from patients with T2D for research purposes. Therefore, the aim was to investigated the presence of GADA in serum of subjects with T2D and its relationship with clinical criteria, metabolic control, drug treatment, and diabetes complications to identify possible patients with LADA in a hospital in southeastern Mexico is worthwhile.
The sample was recruited at the Diabetes Clinic of the Regional Hospital of High Specialty "Dr. Gustavo A. Rovirosa Pérez", in the period from January 2020 to May 2021. The diagnosis was based in accordance with World Health Organization (WHO, 1999) criteria. Inclusion criteria: 1) patients previously diagnosed with T2D, 2) absence of insulin requirement for at least 6 months after diagnosis, 3) > 30 and < 50 years old at diabetes diagnosis, 4) BMI < 40 kg/m2, 5) subjects who agreed to participate in the study and signed the informed consent before the interview.
Serum GADA and other biochemical concentrations were determined by an enzymatic immunoassay method (Human Anti-Glutamic Acid Decarboxylase ELISA Kit; MyBioSource).
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Tabasco
-
Villahermosa, Tabasco, Mexico, 86090
- Isela Esther Juarez Rojop
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients previously diagnosed with T2D,
- absence of insulin requirement for at least 6 months after diagnosis,
- > 30 and < 50 years old at diabetes diagnosis,
- BMI < 40 kg/m2,
- subjects who agreed to participate in the study and signed the informed consent before the interview.
Exclusion Criteria:
• patients with other types of diabetes, and subjects who did not agree to participate.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GADA in serum of subjects with T2D
Time Frame: May 2021
|
Serum GADA concentrations were determined by an enzymatic immunoassay method in subjects with T2D
|
May 2021
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LADA-DACS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Latent Autoimmune Diabetes
-
Children's Hospital of PhiladelphiaCompletedLatent Autoimmune Diabetes in AdultUnited States, United Kingdom
-
Diamyd Therapeutics ABCompletedLatent Autoimmune Diabetes in Adult (LADA)Sweden
-
Abertawe Bro Morgannwg University NHS TrustNovo Nordisk A/SUnknownLatent Autoimmune Diabetes in Adults LADAUnited Kingdom
-
DeveloGen Israel, Ltd.Terminated
-
Norwegian University of Science and TechnologyKarolinska Institutet; Linkoeping University; St. Olavs Hospital; Diamyd Medical...CompletedLatent Autoimmune Diabetes in AdultsNorway, Sweden
-
Norwegian University of Science and TechnologyWithdrawn
-
Karolinska InstitutetNovo Nordisk A/S; The Swedish Research Council; Swedish Council for Working Life...CompletedType 2 Diabetes | Latent Autoimmune Diabetes in AdultsSweden
-
University of WashingtonGlaxoSmithKline; Seattle Institute for Biomedical and Clinical ResearchCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Exerscrip...RecruitingType 1 Diabetes | Pancreatitis | Latent Autoimmune Diabetes in AdultsUnited States
-
Instituto Nacional de Salud Publica, MexicoWithdrawnDiabetes Mellitus | Latent Tuberculosis